Clinical Trials Logo

Thromboembolic Events clinical trials

View clinical trials related to Thromboembolic Events.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06238115 Recruiting - Clinical trials for Thromboembolic Events

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

TEAR
Start date: March 4, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To explore whether administering tirofiban in stent-assisted coiling/flow diverting treatments for participants with unruptured intracranial aneurysms can reduce new ischemic lesions on postoperative DWI sequences compared to conventional dual antiplatelet therapy.

NCT ID: NCT04115436 Recruiting - Clinical trials for Thromboembolic Events

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

GSAF
Start date: October 1, 2019
Phase:
Study type: Observational

Life-long therapy with oral anticoagulants (OAC) is strongly recommended in AF patients receiving left atrial appendage isolation (LAAI) to prevent thromboembolic (TE) events. However, some patients are observed to remain stroke-free while off OACs for years whereas others experience TE events if OAC is discontinued even for a short period of time. Therefore, we aim to evaluate the association of genetic variants (single nucleotide polymorphisms - SNPs) with off-anticoagulation stroke-risk in AF patients.

NCT ID: NCT02342444 Recruiting - Surgery Clinical Trials

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

Start date: February 2014
Phase: Phase 4
Study type: Interventional

The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended by the drug companies. These two doses have never been directly compared in trauma, general, and vascular surgery patients. The purposes of this study are: 1. to compare the development of blood clots in patients receiving 30mg twice daily of enoxaparin compared to patients receiving 40mg once daily of enoxaparin. 2. to determine if there is higher risk of bleeding complications in patients receiving 30mg twice daily of enoxaparin compared to patients receiving 40mg once daily. Patients enrolled into the study will be randomized to receive enoxaparin, 30mg twice daily or enoxaparin, 40mg once daily. Patients will then be monitored for signs and symptoms of blood clots. At the time of discharge (or before, if medically indicated), an ultrasound test will be performed to look for blood clots in the patient's legs. The investigators will compare incidence of blood clots formed between the 2 groups of patients to determine if one dose of enoxaparin relates to a lower rate of blood clots in critically ill patients. The investigators will also compare the incidence of bleeding complications between the 2 groups.